Report: Psoriatic arthritis market to cross $3.7 billion by 2023
- In 2013, five TNA-alpha inhibitors dominated the psoriatic arthritis (PsA) marketplace, with Humira (adalimumab) in the number one spot.
- Analysts predict that several new PsA treatments will emerge as market leaders, including Pfizer’s Xeljanz (tofacitinib), Janssen’s Stelara (ustekinumab), and Celgene’s Otezla (apremilast).
- The market will also shift as biosimilar versions of Humira, Enbrel (entanercept), and Remicade (infliximab) from J&J/Merck become available.
There are a slew of much-needed PsA therapies coming into the market over the next decade. Not only are there multiple disease manifestations to address in PsA patients, there are many TNF-alpha inhibitor-refractory patients.
While the mainstay of treatment will continue to be TNF-alpha inhibitors and disease-modifying anti-rheumatic drugs (DMARDs), the demand for additional treatment options with novel modes of action is strong. Analysts predict that Xeljanz will experience the greatest uptake by 2023, in part because of the convenience of its oral formulation. All told, these new production introductions bode well for PsA patients and sets up a robust treatment market, as does the advent of biosimilar Remicade, which will launch in 2015.